Ignite Creation Date:
2024-05-05 @ 5:28 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00463268
Status:
COMPLETED
Last Update Posted:
2013-05-29
First Post:
2007-04-19
Brief Title:
Osteoporosis Prevention With Low Dose Alendronate
Sponsor:
University Hospital of Mont-Godinne
Organization:
University Hospital of Mont-Godinne
Study Overview
Official Title:
Prevention of Postmenopausal Bone Loss in Osteopenic Women With Alendronate Given on a 70 mg Once-every Two Week Regimen a 2-year Double-blind Placebo-controlled Clinical Trial
Status:
COMPLETED
Status Verified Date:
2013-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the efficacy of the intermittent administration of alendronate in a low dose 70 mg once every two week as osteoporosis prevention for menopausal osteopenic patients who dont want or cant receive an oestrogenic substitution treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None